When is Nurtec Expected to Go Generic?
The patent exclusivity for Nurtec ODT (rimegepant) is anticipated to expire in 2032 [1][2]. This timeline allows for a period of market exclusivity for the branded drug before generic versions can be introduced.
What is Nurtec and What Does it Treat?
Nurtec ODT is an oral prescription medication used for the acute treatment of migraine with or without aura in adults [3]. It is also used for the preventive treatment of episodic migraine in adults [3]. The active ingredient in Nurtec ODT is rimegepant [3].
How Does Nurtec Work?
Nurtec ODT belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists [3]. CGRP is a molecule that plays a role in migraine pain [3]. By blocking the action of CGRP at its receptor, Nurtec ODT helps to alleviate migraine pain and associated symptoms [3].
Are There Any Patent Challenges for Nurtec?
The patent landscape for pharmaceuticals can be complex, and patents can be subject to legal challenges [4]. Information regarding specific patent challenges for Nurtec ODT is not provided here. However, companies often seek to extend the market exclusivity of their drugs through various legal and regulatory means [4].
What Happens After Nurtec's Patent Expires?
Following the expiration of patent exclusivity, generic manufacturers can seek approval to market their versions of the drug [2]. Generic drugs contain the same active ingredient as the brand-name drug and are required to be bioequivalent [2]. The introduction of generics typically leads to a significant decrease in drug prices due to increased competition [2].
How Does Nurtec Compare to Other Migraine Treatments?
Nurtec ODT is one of several treatment options available for migraine. Other CGRP inhibitors, both injectable and oral, are also used for migraine treatment [5]. These may include medications like Aimovig, Ajovy, Emgality, and Ubrelvy, among others [5]. The choice of treatment depends on individual patient needs, migraine characteristics, and physician recommendations [5].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/nurtec-odt
[2] https://www.drugpatentwatch.com/blog/understanding-drug-patent-expiration
[3] https://www.nurtec.com/
[4] https://www.drugpatentwatch.com/blog/understanding-the-drug-patent-litigation-process
[5] https://www.mayoclinic.org/diseases-conditions/migraine-headache/in-depth/migraine-treatment/art-20047531